Open
CytoArm為快速、非病毒基因轉殖、高純度且成本合宜之新型腫瘤專一性T細胞建置平台，不需進行基因轉殖且再現性佳，可於十天內將病患之白血球轉化並增殖為腫瘤專一性T細胞 (純度>90%) 已成功開發多種BsAb armed T產品原型，於動物試驗證實可有效治療各類癌症(血癌、實體腫瘤、惡性轉移腫瘤)，且不會產生過度細胞激素釋放或顯著活體毒性。
CytoArm, established in 2020, focuses on developing a novel cancer-specific T cell therapeutic technology. Multiple products of the advanced platform have been demonstrated as effective treatments for blood cancer, solid tumor and malignant metastatic tumor in preclinical animal studies.
CytoArm, established in 2020, focuses on developing a novel cancer-specific T cell therapeutic technology. Multiple products of the advanced platform have been demonstrated as effective treatments for blood cancer, solid tumor and malignant metastatic tumor in preclinical animal studies.